natgillin/translations-raw huggingface dataset:
Assessment of serum aminotransferases (e.g. alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and total bilirubin levels are recommended prior to treatment initiation and during treatment as clinically indicated.
aspartat aminotransferaze (AST)) i razine ukupnog bilirubina kako je klinički indicirano.
Patients with serious infections should not start treatment with Tecfidera until the infection(s) is resolved.
Bolesnici s ozbiljnim infekcijama ne smiju započeti liječenje
Accumulation of parent drug or monomethyl fumarate does not occur with multiple doses of dimethyl fumarate at the therapeutic regimen.
U terapijskom režimu s višestrukim dozama dimetilfumarata ne dolazi do nakupljanja izvornog lijeka ili monometilfumarata.
The mechanism of dimethyl fumarate induced anaphylaxis is unknown.
Mehanizam kojim dimetilfumarat izaziva anafilaksiju nije poznat.
This resulted in a minimal accumulation of exposure yielding an increase in the median Cmax of 12% compared to the twice daily dosing (1.72 mg/l for twice daily compared to 1.93 mg/l for three times daily) with no safety implications.
(1,72 mg /l za dva puta dnevno u usporedbi sa 1,93 mg /l za tri puta dnevno) bez sigurnosnih implikacija.
Consider withholding Tecfidera treatment in patients with serious infections until the infection has resolved (see section 4.8).
U bolesnika s ozbiljnim herpes zoster infekcijama potrebno je razmotriti prekid liječenja lijekom Tecfidera dok se infekcija ne razriješi (vidjeti dio 4.8).
Oral administration of dimethyl fumarate at 25, 100, and 250 mg/kg/day to rats during pregnancy and lactation resulted in lower body weights in the F1 offspring, and delays in sexual maturation in F1 males at 11 times the recommended dose on an AUC basis.
Peroralna primjena dimetilfumarata od 25, 100 i 250 mg/kg/dan štakoricama tijekom gravidnosti i laktacije rezultirala je nižim tjelesnim težinama u F1 potomstvu i kašnjenjem u seksualnom sazrijevanju mužjaka F1 potomstva kod doze 11 puta veće od preporučene na temelju AUC-a.
Administration of dimethyl fumarate at oral doses of 25, 100, and 250 mg/kg/day to pregnant rats during the period of organogenesis resulted in maternal adverse effects at 4 times the recommended dose on an AUC basis, and low fetal weight and delayed ossification (metatarsals and hindlimb phalanges) at 11 times the recommended dose on an AUC basis.
Primjena dimetilfumarata u oralnim dozama od 25, 100 i 250 mg/kg/dan gravidnim štakoricama tijekom razdoblja organogeneze rezultirala je nuspojavama kod majke pri dozi 4 puta većoj od preporučene na temelju AUC-a i niskoj težini fetusa i usporenom okoštavanju (metatarzalne falange i falange stražnjih nogu) pri dozi 11 puta većoj od preporučene na temelju AUC-a.
Herpes zoster infections have been reported with Tecfidera use.
Uz primjenu lijeka Tecfidera prijavljeni su slučajevi herpes zoster infekcija.
Methacrylic acid - methyl methacrylate copolymer (1:1) Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30% Simeticone
celuloza, mikrokristalična karmelozanatrij, umrežena talk silicijev dioksid, koloidni bezvodni magnezijev stearat trietilcitrat metakrilatna kiselina - metilmetakrilat kopolimer (1:1) metakrilatna kiselina - etilakrilat kopolimer (1:1) 30% disperzija simetikon natrijev laurilsulfat polisorbat 80
Keep this medicine out of the sight and reach of children.
Prije uporabe pročitajte uputu o lijeku Čuvati izvan pogleda i dohvata djece
Elevations in transaminases ≥3 times ULN with concomitant elevations in total bilirubin >2 times ULN, were not observed in placebo-controlled studies.
U placebom kontroliranim ispitivanjima nisu opažena povišenja transaminaza ≥3 puta GGN s istodobno povišenim razinama ukupnog bilirubina >2 puta GGN.
Cases of anaphylaxis/anaphylactoid reaction have been reported following Tecfidera administration in the post-marketing setting.
Nakon stavljanja lijeka u promet prijavljeni su slučajevi anafilaksije/anafilaktoidne reakcije nakon primjene Tecfidere.
In the majority of patients who experienced flushing, it was mild or moderate in severity.
većine bolesnika kod kojih se pojavila navala crvenila, ona je bila blaga ili umjerena.
Tel: +385 (0) 1 230 34 46
Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46
The incidence of serious flushing, which may be characterised by generalised erythema, rash and/or pruritus, was seen in less than 1% of patients treated with Tecfidera (see sections 4.2, 4.4 and 4.5).
Incidencija ozbiljne navale crvenila, koje se može karakterizirati kao generalizirani eritem, osip i/ili pruritus, javila se u manje od 1% bolesnika liječenih
If you have a serious infection (such as pneumonia), talk to your doctor immediately proteins (albumin) in urine increase in levels of liver enzymes (ALT, AST) in the blood
- proteini (albumin) u mokraći - povišena razina jetrenih enzima (ALT, AST) u krvi
Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5.1 for important information on the populations for which efficacy has been established).
(vidjeti dio 5.1 za važne informacije o populacijama za koje je ustanovljena djelotvornost).
Treatment initiation
Način primjene
Consumption of more than a small quantity (more than 50 ml) of strong alcoholic drinks (more than 30% alcohol by volume, e.g. spirits) should be avoided within an hour of taking Tecfidera, as alcohol can interact with this medicine.
Konzumiranje više nego samo malih količina (više od 50 ml) jakih alkoholnih pića (s više od 30%
Tecfidera has not been studied in patients with renal or hepatic impairment.
Oštećenje bubrega i jetre Tecfidera nije ispitivana u bolesnika s oštećenjem bubrega ili jetre.
Leucopenia
Limfopenija
Dyspnoea1
nepoznato dispneja1
The apparent volume of distribution following oral administration of 240 mg dimethyl fumarate varies between 60 L and 90 L. Human plasma protein binding of monomethyl fumarate generally ranges between 27% and 40%.
Distribucija Prividni volumen distribucije nakon peroralne primjene 240 mg dimetilfumarata varira između 60 l i
If you forget or miss a dose, do not take a double dose.
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
Each gastro-resistant hard capsule contains 240 mg dimethyl fumarate
Jedna tvrda želučanootporna kapsula sadrži 240 mg dimetilfumarata
Grade 2 and 3 lymphopenia prevailed in subjects with concurrent lymphocytopenia.
Među ispitanicima s istodobnom limfocitopenijom prevladavala je limfopenija 2. i 3. stupnja.
The capsule or its contents should not be crushed, divided, dissolved, sucked or chewed as the enteric-coating of the microtablets prevents irritant effects on the gut.
Kapsulu ili njezin sadržaj ne smije se zdrobiti, razdijeliti, otopiti,
If you have taken too many capsules, talk to your doctor straight away.
Ako imate ozbiljnu infekciju (kao što je upala pluća), razgovarajte odmah sa svojim liječnikom.
RRMS aged 13 to 17 years (4 patients aged ≤14 years).
Tecfidera je procijenjena u prospektivnom otvorenom nekontroliranom ispitivanju u 22 pedijatrijska bolesnika s RRMS-om u dobi od 13 do 17 godina (4 bolesnika u dobi od ≤14 godina).
Side effects which may show up in your blood or urine tests low levels of white blood cells (lymphopenia, leucopenia) in the blood.
- niska razina bijelih krvnih stanica (limfopenija, leukopenija) u krvi.
Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules
Tecfidera 120 mg tvrde želučanootporne kapsule Tecfidera 240 mg tvrde želučanootporne kapsule
Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Tecfidera in patients with Relapsing Remitting MS. Long term (> 4 weeks) continuous use of acetylsalicylic acid has not been studied (see sections 4.4 and 4.8).
Dugotrajna (> 4 tjedna) neprekidna upotreba acetilsalicilatne kiseline nije ispitana (vidjeti dijelove 4.4 i 4.8).
Severe renal and hepatic impairment
Teško oštećenje bubrega i jetre
Each gastro-resistant hard capsule contains 120 mg dimethyl fumarate
Jedna tvrda želučanootporna kapsula sadrži 120 mg dimetilfumarata
Renal tubular hyperplasia was observed in rats with life time dosing (2-year study).
U štakora s doživotnim doziranjem (2-godišnje ispitivanje) primijećena je bubrežna tubularna hiperplazija.
Feeling hot
Česte nuspojave
Starting dose 120 mg twice a day.
120 mg dva puta na dan
Hypoxia1
nepoznato hipoksija1
Tecfidera 240mg gastro-resistant hard capsules
Tecfidera 240 mg tvrde želučanootporne kapsule
Contents of the pack and other information
Kako čuvati Tecfideru Sadržaj pakiranja i druge informacije
MT Ltd. Tel: +356 21337008
Tel: +356 21337008
Biogen Hungary Kft. Tel: + 36 1 899 9883
Tel: + 36 1 899 9883
Package leaflet: Information for the patient Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 120 mg tvrde želučanootporne kapsule Tecfidera 240 mg tvrde želučanootporne kapsule dimetilfumarat (dimethylis fumaras)
Tecfidera 240 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 240 mg tvrde želučanootporne kapsule dimetilfumarat
Tecfidera 120 mg gastro-resistant hard capsules dimethyl fumarate
Tecfidera 120 mg tvrde želučanootporne kapsule dimetilfumarat
Morning Evening Mon.
Ujutro
What Tecfidera is and what it is used for What you need to know before you take Tecfidera How to take Tecfidera
Što morate znati prije nego počnete uzimati Tecfideru
Four per cent (4%) of patients treated with Tecfidera discontinued due to gastrointestinal events.
bolesnika liječenih Tecfiderom prekinulo je liječenje zbog gastrointestinalnih smetnji.
The incidence of the adverse reactions below are expressed according to the following categories:
Zbog dizajna ispitivanja, bolest s visokom aktivnošću je definirana kako slijedi:
Tecfidera 120 mg gastro-resistant hard capsules are green and white and printed with ‘BG-12 120 mg' and are available in packs containing 14 capsules.
„BG-12 120 mg“ i dostupne su u pakiranju od 14 kapsula.
Skin and subcutaneous tissue disorders
Poremećaji bubrega i mokraćnog sustava proteinurija često
Tecfidera 120mg gastro-resistant hard capsules
Tecfidera 120 mg tvrde želučanootporne kapsule
Magnesium stearate
Mjere ishoda MRb
Nervous system disorders
Poremećaji živčanog sustava osjećaj žarenja često
Flushing and gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing and gastrointestinal events, these events may continue to occur intermittently throughout treatment with Tecfidera.
(prvenstveno u prvom mjesecu), a bolesnici kod kojih se pojave navala crvenila i gastrointestinalne smetnje mogu ih i dalje povremeno imati tijekom cijelog liječenja Tecfiderom.
Cases of herpes zoster have occurred with Tecfidera.
Tijekom primjene lijeka Tecfidera pojavili su se slučajevi herpes zostera.
Herpes zoster (shingles) may occur with Tecfidera treatment.
Tijekom liječenja lijekom Tecfidera može doći do pojave herpes zostera.
There was no case explicitly reporting Fanconi syndrome in the Multiple Sclerosis (MS) indication; however, it has been reported in literature that that female patients with psoriasis treated long-term with fumaric acid esters seem to be at particular risk.
međutim, u literaturi je zabilježeno da bolesnice s psorijazom koje su dugotrajno liječene esterima fumaratne kiseline mogu biti pod osobitim rizikom.
Tel: +39 02 5849901
Biogen Italia s.r.l. Tel: +39 02 5849901
The Package leaflet should be updated accordingly.
U skladu s time potrebno je ažurirati i uputu o lijeku.
Biogen Netherlands B.V. Tel: +31 20 542 2000
Biogen Poland Sp. z o.o. Tel: +48 22 351 51 00
Gelatin
Čet
Rate ratio
Prijavljivanje nuspojava
Burning sensation
Tablični sažetak nuspojava
Tel: +421 2 323 340 08
Biogen Slovakia s.r.o. Tel: +421 2 323 340 08
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava limfopenija često leukopenija često trombocitopenija manje često
Tecfidera is for oral use
Za što se koristi Tecfidera
Common White blood cell count decreased Common 1 Adverse reactions derived only during post marketing experience
1 Nuspojave koje potječu samo iz iskustva nakon stavljanja lijeka u promet Opis izdvojenih nuspojava
Hepatic impairment
Kliničke mjere ishodaa
The study lasted six months.
Ispitivanje je trajalo šest mjeseci.
Similar results were seen in the second study after a year.
Slične rezultate pokazalo je drugo ispitivanje nakon jedne godine.
The full EPAR for Adenuric can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Cjeloviti EPAR za lijek Adenuric nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It is available as tablets (80 and 120 mg).
Dostupan je u obliku tableta (80 i 120 mg).
These side effects were mostly mild or moderate in severity.
Ove su nuspojave većinom bile blage ili umjerene.
Adenuric should be started two days before chemotherapy and continued for at least 7 days.
Liječenje Adenuricom treba započeti dva dana prije kemoterapije i nastaviti najmanje 7 dana.
Adenuric febuxostat
Adenuric febuksostat
The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Adenuric na snazi u Europskoj uniji od 21. travnja 2008.
Patients received either Adenuric or allopurinol for 7 to 9 days.
Bolesnici su primali Adenuric ili alopurinol tijekom 7 do 9 dana.
The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/dl.
Glavni pokazatelj djelotvornosti bio je broj bolesnika u kojih su posljednje tri razine mokraćne kiseline u krvi bile niže od 6 mg/dl.
What measures are being taken to ensure the safe and effective use of Adenuric?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Adenuric?
For more information about treatment with Adenuric, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Adenuric pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite se svom liječniku ili ljekarniku.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adenuric.
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenilo lijek da bi donijelo svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Adenuric.
In both studies, allopurinol was used at a dose of 300 mg once a day, except in patients with kidney problems, who took 100 mg.
U oba ispitivanja korištene su doze od 300 mg alopurinola jedanput na dan, osim u ispitanika s bubrežnim problemima, koji su uzimali 100 mg.
Other information about Adenuric
Ostale informacije o lijeku Adenuric
Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric.
Tijekom prvih nekoliko mjeseci liječenja može doći do napada gihta te se preporučuje uzimanje drugih lijekova za sprječavanje napada gihta tijekom najmanje prvih šest mjeseci liječenja Adenuricom.
Adenuric treatment should not be stopped if an attack of gout occurs.
Liječenje Adenuricom ne treba prekidati u slučaju napada gihta.
A risk management plan has been developed to ensure that Adenuric is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Adenuric.
Adenuric is a medicine that contains the active substance febuxostat.
Adenuric je lijek koji sadrži djelatnu tvar febuksostat.
This is a summary of the European public assessment report (EPAR) for Adenuric.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Adenuric.
In patients with blood cancer who were undergoing chemotherapy, Adenuric was as effective as allopurinol in controlling blood levels of uric acid: in 98.3 % of patients (170 out of 173) on Adenuric blood levels of uric acid normalised compared with 96 % (166 out of 173) of patients on allopurinol.
U bolesnika s rakom krvi koji su primali kemoterapiju, Adenuric je bio jednako djelotvoran kao alopurinol u kontroli razine mokraćne kiseline u krvi: razina mokraćne kiseline u krvi normalizirala se u 98,3 % bolesnika (170 od 173) koji su uzimali Adenuric, u usporedbi s 96 % (166 od 173) bolesnika koji su uzimali alopurinol.
Blood uric acid levels were measured every month.
Mjerenja razine mokraćne kiseline u krvi provodila su se svaki mjesec.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom decilitru) nakon dva do četiri tjedna.
For the treatment of long-term hyperuricaemia, the recommended dose of Adenuric is 80 mg once a day.
Za liječenje dugotrajne hiperuricemije preporučena doza Adenurica iznosi 80 mg jedanput na dan.
This was compared with 22% of the patients taking allopurinol (60 out of 268) and none of the 134 patients taking placebo.
Ti rezultati uspoređeni su s 22 % bolesnika koji su uzimali alopurinol (60 od 268) i nijednim od 134 bolesnika koji su uzimali placebo.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adenuric, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Adenuric nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood).
Adenuric se koristi za liječenje odraslih osoba s dugotrajnom hiperuricemijom (visoka razina mokraćne kiseline ili „urata” u krvi).
The main measure of effectiveness was based on their blood uric acid levels.
Glavni pokazatelj djelotvornosti temeljio se na razini mokraćne kiseline u krvi.
In the first study, 48% of the patients taking 80 mg Adenuric once a day (126 out of 262) and 65% of the patients taking 120 mg once a day (175 out of 269) had levels of uric acid below 6 mg/dl in the final three measurements.
U prvom ispitivanju, u 48 % bolesnika koji su uzimali 80 mg Adenurica jedanput na dan (126 od 262) i u 65 % bolesnika koji su uzimali 120 mg jedanput na dan (175 od 269) razine mokraćne kiseline bile su niže od 6 mg/dl u posljednja tri mjerenja.
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day.
Za sprječavanje i liječenje hiperuricemije u bolesnika podvrgnutih kemoterapiji preporučena doza iznosi 120 mg jedanput na dan.
Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage).
Adenuric se koristi u bolesnika koji već pokazuju znakove nakupljanja kristala, uključujući urični artritis (bol i upala zglobova) ili tofi („kamenac”, veće nakupine kristala urata koje mogu izazvati oštećenje zglobova i kosti).
Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys.
Hiperuricemija može dovesti do stvaranja kristala urata i njihovog nakupljanja u zglobovima i bubrezima.
The first study, carried out in 1,072 patients, compared three doses of Adenuric (80, 120 and 240 mg once a day) with placebo (a dummy treatment) and allopurinol (another medicine used to treat hyperuricaemia).
U prvom ispitivanju, koje je obuhvaćalo 1072 bolesnika, uspoređivane su tri doze Adenurica (80, 120 i 240 mg jedanput na dan) s placebom (liječenje bez djelatne tvari) i alopurinolom (drugi lijek za liječenje hiperuricemije).
In patients who are on chemotherapy a reduction in uric acid levels is expected to reduce the risk of tumour lysis syndrome.
U bolesnika koji su podvrgnuti kemoterapiji, očekuje se da se smanjenjem razine mokraćne kiseline smanji opasnost od sindroma tumorske lize.
Adenuric is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are on chemotherapy and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).
Adenuric se također koristi za liječenje i sprječavanje visoke razine mokraćne kiseline u krvi u odraslih koji primaju kemoterapiju za rak krvi i kod kojih postoji opasnost od nastanka sindroma tumorske lize (komplikacija koja nastaje zbog uništavanja stanica raka, pri čemu dolazi do naglog porasta mokraćne kiseline u krvi, što može izazvati oštećenje bubrega).
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, Adenuric has been studied in one main study involving 346 adult patients undergoing chemotherapy for blood cancer.
Za sprječavanje i liječenje hiperuricemije u bolesnika podvrgnutih kemoterapiji, provedeno je jedno glavno ispitivanje na 346 odraslih bolesnika podvrgnutih kemoterapiji za liječenje raka krvi.
What is the risk associated with Adenuric?
Koji su rizici povezani s lijekom Adenuric?
What is Adenuric?
Što je Adenuric?
The most commonly reported side effects with Adenuric are gout flare-ups, abnormal liver test results, diarrhoea, nausea (feeling sick), headache, rash and oedema (swelling).
Najčešće prijavljivane nuspojave lijeka Adenuric su napadi gihta, poremećaji jetrene funkcije, proljev, mučnina, glavobolja, osip i edem (oteklina).
The second study compared two doses of Adenuric (80 and 120 mg once a day) with allopurinol over one year in 762 patients.
U drugom ispitivanju uspoređivane su dvije doze Adenurica (80 i 120 mg jedanput na dan) s alopurinolom na 762 bolesnika tijekom jedne godine.
For the treatment of hyperuricaemia and gout, Adenuric has been studied in two main studies involving a total of 1,834 patients.
Za liječenje hiperuricemije i gihta provedena su dva glavna ispitivanja lijeka Adenuric na ukupno 1834 bolesnika.
The CHMP concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels including in patients undergoing chemotherapy , but that it could carry a greater risk of side effects affecting the heart and blood vessels.
CHMP je zaključio da je Adenuric djelotvorniji od alopurinola u smanjivanju razine mokraćne kiseline u krvi, uključujući i u bolesnika podvrgnutih kemoterapiji, no da može podrazumijevati veću opasnost od nuspojava povezanih sa srcem i krvnim žilama.
When this happens in the joints and causes pain, it is known as ‘gout'.
Nakupljanje kristala u zglobovima izaziva bol koja se naziva „giht”.
The Committee decided that Adenuric's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je odlučio da koristi lijeka Adenuric nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
Why has Adenuric been approved?
Zašto je lijek Adenuric odobren?
This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120
Time se obično smanjuje razina mokraćne kiseline u krvi unutar dva tjedna, no doza se može povećati na 120 mg jedanput na dan ako razina mokraćne kiseline u krvi ostane visoka (više od 6 mg po
The active substance in Adenuric, febuxostat, reduces the formation of uric acid.
Djelatna tvar lijeka Adenuric, febuksostat, smanjuje nastajanje mokraćne kiseline.
Adenuric was more effective than allopurinol and placebo in treating hyperuricaemia by reducing blood uric acid levels.
Adenuric je pokazao veću djelotvornost u liječenju hiperuricemije nego alopurinol i placebo smanjujući razinu mokraćne kiseline u krvi.